Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment.
about
Bayesian evaluation of a physiologically-based pharmacokinetic (PBPK) model of long-term kinetics of metal nanoparticles in ratsToxicity testing in the 21st century: a vision and a strategySimulating microdosimetry in a virtual hepatic lobuleDatabase for physiologically based pharmacokinetic (PBPK) modeling: physiological data for healthy and health-impaired elderly.A Workflow for Global Sensitivity Analysis of PBPK Models.Application of physiologically based pharmacokinetic models in chemical risk assessment.Application of a Physiologically Based Pharmacokinetic Model to Study Theophylline Metabolism and Its Interactions With Ciprofloxacin and Caffeine.Whole-body physiologically based pharmacokinetic models.Approaches for applications of physiologically based pharmacokinetic models in risk assessment.MEGen: A Physiologically Based Pharmacokinetic Model Generator.The use of PBPK models to inform human health risk assessment: case study on perchlorate and radioiodide human lifestage models.Quantitative InSilico analysis of transient metabolism of acetaminophen and associatedcauses of hepatotoxicity in humans.Extrahepatic metabolism by CYP2E1 in PBPK modeling of lipophilic volatile organic chemicals: impacts on metabolic parameter estimation and prediction of dose metrics.Challenges Associated with Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making.Comparing models for quantitative risk assessment: an application to the European Registry of foreign body injuries in children.Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation.Biologically Motivated Approaches to Extrapolation from High to Low Doses and the Advent of Systems Biology: The Road to Toxicological Safety Assessment
P2860
Q23917058-2E067769-3E66-4355-9F51-0988DC3C859BQ27921848-79706784-E219-43D5-8902-A82E10C46EDBQ28473754-7F7E149B-E804-41F2-B87B-B94B1E4F9602Q33396717-6EAC3A37-71DF-4B0F-9E43-9EFF3D2970B5Q35084469-ED8BF516-CE2F-47AB-8B9E-947FC371BDF5Q35864986-79F46873-73F7-4A2C-81DB-CD8EE43851C7Q36600064-2F7703DF-00BA-4E5E-92CD-AA0D0C0A1901Q36788418-50EC58D9-5143-42B4-BA8B-EA80EA98B0B6Q37201545-65AD3F8C-01A7-439D-9D79-54A313FF1C9BQ39017720-554C78D1-7544-483F-B501-E42C7DF0FE5CQ44148351-B0AF9A1B-D58E-43EA-B26E-7817696BFA4CQ47126152-D22A8159-3190-4A6C-8CEF-5E1432409455Q48571911-94954760-2569-4E3B-AD29-661BCF5840A9Q49551649-278654B5-58DE-48DB-8739-09C8A078AC1DQ51253863-E694E84D-AC61-4505-93CE-8DAD2632B3A0Q53236816-1E80F214-B068-4565-ADF2-2DB989C5502BQ57543250-001C0CE2-8429-4C12-AC30-1E638FEE443D
P2860
Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Framework for evaluation of ph ...... in safety or risk assessment.
@ast
Framework for evaluation of ph ...... in safety or risk assessment.
@en
type
label
Framework for evaluation of ph ...... in safety or risk assessment.
@ast
Framework for evaluation of ph ...... in safety or risk assessment.
@en
prefLabel
Framework for evaluation of ph ...... in safety or risk assessment.
@ast
Framework for evaluation of ph ...... in safety or risk assessment.
@en
P2093
P2860
P1433
P1476
Framework for evaluation of ph ...... in safety or risk assessment.
@en
P2093
Hugh A Barton
Leona H Clark
R Woodrow Setzer
P2860
P304
P356
10.1111/J.0272-4332.2004.00561.X
P577
2004-12-01T00:00:00Z